蔚蓝生物
(603739)
| 流通市值：32.21亿 | | | 总市值：32.21亿 |
| 流通股本：2.53亿 | | | 总股本：2.53亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 709,615,819.06 | 345,050,139.43 | 1,366,123,678.63 | 1,015,793,037.32 |
| 营业收入 | 709,615,819.06 | 345,050,139.43 | 1,366,123,678.63 | 1,015,793,037.32 |
| 二、营业总成本 | 657,262,341.14 | 319,210,567.09 | 1,281,214,678.35 | 946,888,887.21 |
| 营业成本 | 397,995,074.74 | 192,439,618.52 | 754,152,389.76 | 564,304,405.47 |
| 税金及附加 | 8,268,329.36 | 4,067,645.58 | 15,749,985.91 | 10,745,176.45 |
| 销售费用 | 103,937,095.9 | 50,068,547.17 | 202,232,485.89 | 154,231,257.39 |
| 管理费用 | 75,260,089.09 | 37,630,713.71 | 150,929,595.67 | 104,152,866.56 |
| 研发费用 | 62,033,752.03 | 30,165,671.63 | 139,212,033.95 | 100,238,559.8 |
| 财务费用 | 9,768,000.02 | 4,838,370.48 | 18,938,187.17 | 13,216,621.54 |
| 其中:利息费用 | 7,747,771.57 | 5,372,144.35 | 17,999,067.05 | 12,413,825.03 |
| 其中:利息收入 | 95,228.8 | -49,737.52 | 761,344.83 | -584,054.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,097,810.44 | -1,980 | 31,643,891.01 | 28,410,589.39 |
| 加:投资收益 | 1,091,181.63 | 3,315,947.06 | -330,637.59 | -1,198,744.89 |
| 资产处置收益 | 46,509 | -69 | 470,744.93 | 398,570.39 |
| 资产减值损失(新) | 86,802.08 | 469.59 | -6,525,877.88 | 863,811.28 |
| 信用减值损失(新) | -5,116,871.23 | -2,176,156.15 | -12,799,100.3 | -8,576,208.89 |
| 其他收益 | 14,723,599.59 | 5,251,667.38 | 30,223,493.96 | 20,752,969.81 |
| 四、营业利润 | 69,282,509.43 | 32,229,451.22 | 127,591,514.41 | 109,555,137.2 |
| 加:营业外收入 | 44,978.86 | 30,035.69 | 376,259.72 | 349,969.29 |
| 减:营业外支出 | 486,306.32 | 28,848.81 | 4,261,856.24 | 1,521,274.18 |
| 五、利润总额 | 68,841,181.97 | 32,230,638.1 | 123,705,917.89 | 108,383,832.31 |
| 减:所得税费用 | 15,501,441.4 | 6,778,651.06 | 26,240,407.24 | 25,453,996.23 |
| 六、净利润 | 53,339,740.57 | 25,451,987.04 | 97,465,510.65 | 82,929,836.08 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 53,339,740.57 | 25,451,987.04 | 97,465,510.65 | 82,929,836.08 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 38,559,770.52 | 17,867,737.01 | 69,809,673.62 | 61,779,150.1 |
| 少数股东损益 | 14,779,970.05 | 7,584,250.03 | 27,655,837.03 | 21,150,685.98 |
| 扣除非经常损益后的净利润 | 22,164,324.36 | 11,349,597.73 | 19,459,179.41 | 22,933,229.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.07 | 0.28 | 0.24 |
| (二)稀释每股收益 | 0.15 | 0.07 | 0.28 | 0.24 |
| 八、其他综合收益 | 83,086.88 | -480,627.11 | 224,554.39 | -219,343.11 |
| 归属于母公司股东的其他综合收益 | 6,085.83 | -357,174.54 | 293,952.42 | -169,834.31 |
| 九、综合收益总额 | 53,422,827.45 | 24,971,359.93 | 97,690,065.04 | 82,710,492.97 |
| 归属于母公司股东的综合收益总额 | 38,565,856.35 | 17,510,562.47 | 70,103,626.04 | 61,609,315.79 |
| 归属于少数股东的综合收益总额 | 14,856,971.1 | 7,460,797.46 | 27,586,439 | 21,101,177.18 |
| 公告日期 | 2026-08-28 | 2026-04-25 | 2026-04-25 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |